Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Johnson & Johnson explores $20 billion sale of orthopedics unit, Bloomberg News reports
Johnson & Johnson explores $20 billion sale of orthopedics unit, Bloomberg News reports
FILE PHOTO: A Johnson & Johnson banner is displayed on the front of the New York Stock Exchange (NYSE) in New York City, in New York City, U.S., December 5, 2023. REUTERS/Brendan McDermid/File Photo · Reuters
Reuters
Fri, February 20, 2026 at 4:49 AM GMT+9 1 min read
In this article:
JNJ
+0.65%
Feb 19 (Reuters) - Johnson & Johnson is preparing a potential sale of the orthopedics unit that it has been planning to separate, with big buyout firms already circling, Bloomberg News reported on Thursday, citing people familiar with the matter.
The business, known as DePuy Synthes, could be valued at more than $20 billion in a sale, according to Bloomberg.
The company did not immediately respond to a Reuters request for comment.
J&J last year said it had planned to separate its orthopedics business into a standalone company within the next 18 to 24 months, marking its second major spinoff in two years as it sharpens focus on higher-growth healthcare segments.
J&J is assembling documents and financials for DePuy Synthes before it meets with possible buyers in the coming weeks, Bloomberg reported.
Several large private equity firms are considering teaming up to potentially buy out the unit, Bloomberg said, adding that the sale could also draw interest from rival medical device players.
J&J’s orthopedics unit makes hip, knee and shoulder implants, surgical instruments and other products and generated $9.3 billion in sales in 2025.
The company’s chief financial officer, Joe Wolk, previously said J&J was exploring multiple paths for the separation, with a primary focus on a tax-free spinoff, but remained open to other options.
He had added that the separation process was already underway, and does not expect further material updates on the transaction until mid-2026.
(Reporting by Sneha S K in Bengaluru; Editing by Maju Samuel)
Terms and Privacy Policy
Privacy Dashboard
More Info